A biomedical engineer at Kennesaw State University has been given a $426,000 grant to build a low-cost device helping to…
Articles by Margarida Maia, PhD
The first patient has been dosed in BEACON, a Phase 1/2 clinical trial of a transplant-based gene-editing stem cell therapy…
Saudi Arabia’s regulatory authorities have approved Casgevy (exagamglogene autotemcel), a one-time gene-editing therapy, to treat sickle cell disease…
A clinical project designed to test whether masitinib, AB Science’s experimental oral therapy for sickle cell disease (SCD), can…
Children and young adults with kidney failure due to sickle cell disease (SCD) wait nearly two times longer for…
More than 1 in 3 children and adolescents with sickle cell disease (SCD) develop retinopathy, or damage to the…
For nearly half of people with sickle cell disease who took part in the Phase 2 part of a…
The U.S. Food and Drug Administration (FDA) is reviewing an application that seeks the approval of exagamglogene autotemcel, a CRISPR-based…
A protein called NLRP12 appears to act as a switch that turns on inflammation and tissue damage when it senses…
People in Ghana with sickle cell disease (SCD) use prevention, monitoring, diagnosis, and treatment to self-manage their condition, but…